News Press Releases

Citi Appointed Depositary Bank for BeiGene, Ltd.'s Sponsored ADR Program

V.ZZE.H | February 8, 2016

Citi’s Issuer Services business, acting through Citibank N.A., has been appointed by BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly targeted and immuno-oncological drugs for the treatment of cancer, as the depositary bank for its American Depositary Receipt (ADR) program.

BeiGene’s ADR program was established through its initial public offering. The ADRs are listed on the NASDAQ under the symbol “BGNE.” Each ADR represents 13 ordinary shares. As a single-listed ADR program, the underlying ordinary shares are not listed or publicly traded in the issuer’s home market.

“Citi is proud to be selected as depositary bank for BeiGene’s ADR program,” said Dirk Jones, Head of Global Issuer Services at Citi. “Citi is committed to providing BeiGene and its investors with the highest quality ADR services.”

Citi is a leading provider of depositary receipt services. With depositary receipt programs in 56 markets, spanning equity and fixed-income products, Citi leverages its global network to provide cross-border capital market access to issuers, intermediaries and investors.

For more information about Citi’s Depositary Receipt Services, please visit www.citi.com/dr.

Citi

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.